- Home
- DFP vs TKNO Comparison
DFP vs TKNO Comparison
Compare DFP & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- TKNO
- Stock Information
- Founded
- DFP 2013
- TKNO 1996
- Country
- DFP United States
- TKNO United States
- Employees
- DFP N/A
- TKNO N/A
- Industry
- DFP Investment Managers
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- DFP Finance
- TKNO Health Care
- Exchange
- DFP Nasdaq
- TKNO Nasdaq
- Market Cap
- DFP 418.8M
- TKNO 430.2M
- IPO Year
- DFP N/A
- TKNO 2021
- Fundamental
- Price
- DFP $20.28
- TKNO $5.59
- Analyst Decision
- DFP
- TKNO Buy
- Analyst Count
- DFP 0
- TKNO 2
- Target Price
- DFP N/A
- TKNO $5.00
- AVG Volume (30 Days)
- DFP 56.2K
- TKNO 446.6K
- Earning Date
- DFP 01-01-0001
- TKNO 03-04-2025
- Dividend Yield
- DFP 6.73%
- TKNO N/A
- EPS Growth
- DFP N/A
- TKNO N/A
- EPS
- DFP N/A
- TKNO N/A
- Revenue
- DFP N/A
- TKNO $37,745,000.00
- Revenue This Year
- DFP N/A
- TKNO $3.47
- Revenue Next Year
- DFP N/A
- TKNO $12.07
- P/E Ratio
- DFP N/A
- TKNO N/A
- Revenue Growth
- DFP N/A
- TKNO 2.89
- 52 Week Low
- DFP $15.45
- TKNO $1.16
- 52 Week High
- DFP $19.31
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- DFP 38.84
- TKNO 29.36
- Support Level
- DFP $20.31
- TKNO $5.16
- Resistance Level
- DFP $20.50
- TKNO $6.62
- Average True Range (ATR)
- DFP 0.18
- TKNO 0.73
- MACD
- DFP -0.03
- TKNO -0.15
- Stochastic Oscillator
- DFP 2.04
- TKNO 6.69
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Pref&Inc Allocation is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.